AU2020337449A1 - Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections - Google Patents

Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections Download PDF

Info

Publication number
AU2020337449A1
AU2020337449A1 AU2020337449A AU2020337449A AU2020337449A1 AU 2020337449 A1 AU2020337449 A1 AU 2020337449A1 AU 2020337449 A AU2020337449 A AU 2020337449A AU 2020337449 A AU2020337449 A AU 2020337449A AU 2020337449 A1 AU2020337449 A1 AU 2020337449A1
Authority
AU
Australia
Prior art keywords
substituted
avibactam
oxy
alkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020337449A
Other languages
English (en)
Inventor
Andrew Nicholls
Carole SABLE
Joaquim Trias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arixa Pharmaceuticals Inc
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Publication of AU2020337449A1 publication Critical patent/AU2020337449A1/en
Priority to AU2024201877A priority Critical patent/AU2024201877B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020337449A 2019-08-29 2020-08-27 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections Abandoned AU2020337449A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201877A AU2024201877B2 (en) 2019-08-29 2024-03-22 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962893612P 2019-08-29 2019-08-29
US62/893,612 2019-08-29
US201962953852P 2019-12-26 2019-12-26
US62/953,852 2019-12-26
PCT/US2020/048119 WO2021041616A1 (en) 2019-08-29 2020-08-27 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201877A Division AU2024201877B2 (en) 2019-08-29 2024-03-22 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Publications (1)

Publication Number Publication Date
AU2020337449A1 true AU2020337449A1 (en) 2022-03-03

Family

ID=72433031

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020337449A Abandoned AU2020337449A1 (en) 2019-08-29 2020-08-27 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections
AU2024201877A Active AU2024201877B2 (en) 2019-08-29 2024-03-22 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201877A Active AU2024201877B2 (en) 2019-08-29 2024-03-22 Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections

Country Status (11)

Country Link
US (3) US20210060033A1 (enExample)
EP (1) EP4021443A1 (enExample)
JP (1) JP7673052B2 (enExample)
KR (1) KR20220054364A (enExample)
CN (1) CN114302725A (enExample)
AU (2) AU2020337449A1 (enExample)
BR (1) BR112022001344A2 (enExample)
CA (1) CA3152300C (enExample)
IL (1) IL290260A (enExample)
MX (1) MX2022002537A (enExample)
WO (1) WO2021041616A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
EP4319760A4 (en) * 2021-04-05 2025-01-08 Qpex Biopharma, Inc. CEFTIBUTENE DOSAGE REGIMEN
JP2024524372A (ja) * 2021-07-01 2024-07-05 キューペックス バイオファーマ， インコーポレイテッド セフチブテンの結晶形態
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
CN116327764B (zh) * 2023-04-06 2024-04-12 浙江医药股份有限公司新昌制药厂 一种高效广谱抗耐药菌的药物组合物及其制备方法和其应用
CN119431373B (zh) * 2024-07-24 2025-08-08 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途
CN122079989A (zh) * 2024-09-30 2026-05-26 科睿迪(南京)医药科技有限公司 二氮杂二环类β-内酰胺酶抑制剂及其应用
WO2026104587A1 (en) 2024-11-13 2026-05-21 Adjutec Pharma As Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046845A1 (en) * 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MX2020004071A (es) 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.

Also Published As

Publication number Publication date
KR20220054364A (ko) 2022-05-02
EP4021443A1 (en) 2022-07-06
WO2021041616A1 (en) 2021-03-04
US20230210863A1 (en) 2023-07-06
US20210060033A1 (en) 2021-03-04
US20260158040A1 (en) 2026-06-11
CA3152300C (en) 2024-04-30
BR112022001344A2 (pt) 2022-06-07
MX2022002537A (es) 2022-03-22
AU2024201877A1 (en) 2024-04-11
AU2024201877B2 (en) 2025-05-08
CA3152300A1 (en) 2021-03-04
JP7673052B2 (ja) 2025-05-08
IL290260A (en) 2022-04-01
CN114302725A (zh) 2022-04-08
JP2022545291A (ja) 2022-10-26

Similar Documents

Publication Publication Date Title
US20230210863A1 (en) Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infections
IL296379B1 (en) Beta-lactamase inhibitors and their uses
JP5961177B2 (ja) 化合物及びその使用
US11008321B2 (en) Crystalline form of an avibactam derivative
JP2025163188A (ja) マイコバクテリア感染症を治療するための、アモキシシリン誘導体とアビバクタム誘導体の組み合わせ経口投与
RU2825281C1 (ru) Вводимые перорально комбинации бета-лактамных антибиотиков и производных авибактама для лечения бактериальных инфекций
JP7437847B2 (ja) レレバクタムの誘導体およびその使用
HK40072825A (en) Orally administered combinations of beta lactam antibiotics and avibactam derivatives for treating bacterial infections
HK40083209A (en) Orally administered combinations of amoxicillin and avibactam derivatives for treating mycobacterial infections
HK40063686A (en) Crystalline form of an avibactam derivative
NZ758795B2 (en) Atropine pharmaceutical compositions
NZ758795A (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
OA16437A (en) Compounds and their use.

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted